700 results on '"Tarr, Philip"'
Search Results
2. Author Correction: Increased prevalence of clonal hematopoiesis of indeterminate potential amongst people living with HIV
- Author
-
Bick, Alexander G., Popadin, Konstantin, Thorball, Christian W., Uddin, Md Mesbah, Zanni, Markella V., Yu, Bing, Cavassini, Matthias, Rauch, Andri, Tarr, Philip, Schmid, Patrick, Bernasconi, Enos, Günthard, Huldrych F., Libby, Peter, Boerwinkle, Eric, McLaren, Paul J., Ballantyne, Christie M., Grinspoon, Steven, Natarajan, Pradeep, and Fellay, Jacques
- Published
- 2022
- Full Text
- View/download PDF
3. Increased prevalence of clonal hematopoiesis of indeterminate potential amongst people living with HIV
- Author
-
Bick, Alexander G., Popadin, Konstantin, Thorball, Christian W., Uddin, Md Mesbah, Zanni, Markella V., Yu, Bing, Cavassini, Matthias, Rauch, Andri, Tarr, Philip, Schmid, Patrick, Bernasconi, Enos, Günthard, Huldrych F., Libby, Peter, Boerwinkle, Eric, McLaren, Paul J., Ballantyne, Christie M., Grinspoon, Steven, Natarajan, Pradeep, and Fellay, Jacques
- Published
- 2022
- Full Text
- View/download PDF
4. Decreased Physical Activity and Prolonged Sitting Time Are Associated With Liver Steatosis in People With HIV
- Author
-
Riebensahm, Carlotta, Berzigotti, Annalisa, Surial, Bernard, Haerry, David, Günthard, Huldrych F; https://orcid.org/0000-0002-1142-6723, Tarr, Philip E, Furrer, Hansjakob, Rauch, Andri, Wandeler, Gilles, Swiss HIV Cohort Study, Riebensahm, Carlotta, Berzigotti, Annalisa, Surial, Bernard, Haerry, David, Günthard, Huldrych F; https://orcid.org/0000-0002-1142-6723, Tarr, Philip E, Furrer, Hansjakob, Rauch, Andri, Wandeler, Gilles, and Swiss HIV Cohort Study
- Abstract
BACKGROUND: Physical activity (PA) regulates intrahepatic storage of fat and reduces the risk of liver steatosis. Given our limited understanding of the pathogenesis of metabolic complications in people with HIV (PWH), it remains unclear whether evidence from the general population can be extrapolated to PWH. We investigated the association between PA and liver steatosis in a single site of the Swiss HIV Cohort Study. METHODS: We screened consecutive Swiss HIV Cohort Study participants using vibration-controlled transient elastography and defined liver steatosis as controlled attenuation parameter ≥248 dB/m. PA was measured using the International PA Questionnaire. We evaluated the association of 3 different measures of PA with liver steatosis in separate multivariable logistic regression models. RESULTS: Of 466 participants, 127 (27.3%) were female, median age was 52 years (interquartile range 43-59), and 244 (52.4%) were overweight (body mass index [BMI] ≥25 kg/m 2 ). Liver steatosis was present in 235 (50.4%) individuals. In multivariable analysis, PA below the recommendations of the European Association for the Study of the Liver was associated with steatosis (adjusted odds ratio, 2.34; 95% confidence interval [CI]: 1.44 to 3.85). Using alternative scales of PA, including metabolic equivalents task minutes (min) per week (adjusted odds ratio 0.76, 95% CI: 0.60 to 0.94) and sitting hours per day (aOR, 1.16; 1.07 to 1.26), yielded comparable results, and associations were similar when we restricted the analyses to lean (BMI <25 kg/m 2 ) subjects. CONCLUSIONS: Insufficient PA and prolonged sitting time were associated with liver steatosis among PWH, independent of BMI. Our results support the importance of promoting PA to prevent liver steatosis in PWH.
- Published
- 2024
5. Incidence of sexually transmitted infections and association with behavioural factors: Time-to-event analysis of a large pre-exposure prophylaxis (PrEP) cohort
- Author
-
Hovaguimian, Frédérique; https://orcid.org/0000-0003-4181-2948, Kouyos, Roger D; https://orcid.org/0000-0002-9220-8348, Kusejko, Katharina; https://orcid.org/0000-0002-4638-1940, Schmidt, Axel J; https://orcid.org/0000-0002-6910-4399, Tarr, Philip E; https://orcid.org/0000-0002-1488-5407, Bernasconi, Enos; https://orcid.org/0000-0002-9724-8373, Braun, Dominique L; https://orcid.org/0000-0003-4036-1030, Calmy, Alexandra; https://orcid.org/0000-0002-1137-6826, Notter, Julia, Stoeckle, Marcel; https://orcid.org/0000-0002-0088-5078, Surial, Bernard; https://orcid.org/0000-0002-1402-974X, Christinet, Vanessa, Darling, Katharine E A; https://orcid.org/0000-0003-1449-3873, Depmeier, Carsten, Läuchli, Severin, Reinacher, Matthias, Rasi, Manuela, Nicca, Dunja; https://orcid.org/0000-0002-4133-8177, Bruggmann, Philip, Haerry, David, Bize, Raphaël; https://orcid.org/0000-0001-5626-4628, Low, Nicola; https://orcid.org/0000-0003-4817-8986, Vock, Florian, El Amari, Emmanuelle Boffi, Böni, Jürg; https://orcid.org/0000-0001-7925-4852, Bosshard, Philipp P; https://orcid.org/0000-0002-1154-2281, Fehr, Jan S, Hampel, Benjamin, SwissPrEPared Cohort Study, Hovaguimian, Frédérique; https://orcid.org/0000-0003-4181-2948, Kouyos, Roger D; https://orcid.org/0000-0002-9220-8348, Kusejko, Katharina; https://orcid.org/0000-0002-4638-1940, Schmidt, Axel J; https://orcid.org/0000-0002-6910-4399, Tarr, Philip E; https://orcid.org/0000-0002-1488-5407, Bernasconi, Enos; https://orcid.org/0000-0002-9724-8373, Braun, Dominique L; https://orcid.org/0000-0003-4036-1030, Calmy, Alexandra; https://orcid.org/0000-0002-1137-6826, Notter, Julia, Stoeckle, Marcel; https://orcid.org/0000-0002-0088-5078, Surial, Bernard; https://orcid.org/0000-0002-1402-974X, Christinet, Vanessa, Darling, Katharine E A; https://orcid.org/0000-0003-1449-3873, Depmeier, Carsten, Läuchli, Severin, Reinacher, Matthias, Rasi, Manuela, Nicca, Dunja; https://orcid.org/0000-0002-4133-8177, Bruggmann, Philip, Haerry, David, Bize, Raphaël; https://orcid.org/0000-0001-5626-4628, Low, Nicola; https://orcid.org/0000-0003-4817-8986, Vock, Florian, El Amari, Emmanuelle Boffi, Böni, Jürg; https://orcid.org/0000-0001-7925-4852, Bosshard, Philipp P; https://orcid.org/0000-0002-1154-2281, Fehr, Jan S, Hampel, Benjamin, and SwissPrEPared Cohort Study
- Abstract
OBJECTIVES: Our objective was to obtain long-term data on the incidence of sexually transmitted infections (STIs) and their association with behavioural factors after widespread pre-exposure prophylaxis (PrEP) implementation. METHODS: This was a time-to-event analysis of a national PrEP cohort in Switzerland (SwissPrEPared study). Participants were people without HIV interested in taking PrEP with at least two STI screening visits. Primary outcomes were incidence rate of gonorrhoea, chlamydia, and syphilis. The association between behavioural factors and STI diagnosis was expressed using hazard ratios. We adjusted for testing frequency and calendar year. RESULTS: This analysis included 3907 participants enrolled between April 2019 and April 2022, yielding 3815.7 person-years of follow-up for gonorrhoea (15 134 screenings), 3802.5 for chlamydia (15 141 screenings), and 3858.6 for syphilis (15 001 screenings). The median age was 39 years (interquartile range [IQR] 32-47), 93.8% (n = 3664) identified as men who have sex with men (MSM). The incidence was 22.8 (95% confidence interval [CI] 21.3-24.4) per 100 person-years for gonorrhoea, 26.3 (95% CI 24.7-28.0) for chlamydia, and 4.4 (95% CI 3.8-5.1) for syphilis. Yearly incidence rates decreased between 2019 (all bacterial STIs: 81.6; 95% CI 59.1-109.9) and 2022 (all bacterial STIs: 49.8; 95% CI 44.6-55.3). Participants reporting chemsex substance use were at higher risk of incident STIs, as were those reporting multiple sexual partners. Younger age was associated with a higher risk of gonorrhoea and chlamydia. CONCLUSIONS: Incidence rates of bacterial STIs decreased over time. Young MSM, those with multiple partners, and those using chemsex substances were at increased risk of STIs.
- Published
- 2024
6. Vaccination des nourrissons et des jeunes enfants contre la varicelle
- Author
-
Gysin, Nicole, primary, Wingeier, Bernhard, additional, Huber, Benedikt, additional, Streuli, Jürg, additional, Fluri, Simon, additional, Guggenheim, Raffael, additional, Gallmann, Caesar, additional, Etter, Gisela, additional, Posfay-Barbe, Klara, additional, and Tarr, Philip, additional
- Published
- 2024
- Full Text
- View/download PDF
7. Varizellen-Impfung der Säuglinge und Kleinkinder
- Author
-
Gysin, Nicole, primary, Wingeier, Bernhard, additional, Huber, Benedikt, additional, Streuli, Jürg, additional, Fluri, Simon, additional, Guggenheim, Raffael, additional, Gallmann, Caesar, additional, Etter, Gisela, additional, Posfay-Barbe, Klara, additional, and Tarr, Philip, additional
- Published
- 2024
- Full Text
- View/download PDF
8. Vaccination contre les HPV
- Author
-
Schwendener, Corina, primary, Kiener, Laura, additional, Wingeier, Bernhard, additional, Gallmann, Caesar, additional, Etter, Gisela, additional, Huber, Benedikt, additional, Bertisch, Barbara, additional, Aebi-Popp, Karoline, additional, Haerry, David, additional, Kind, André, additional, Frey Tirri, Brigitte, additional, Broglie, Martina, additional, and Tarr, Philip, additional
- Published
- 2024
- Full Text
- View/download PDF
9. HPV-Impfung
- Author
-
Schwendener, Corina, primary, Kiener, Laura, additional, Wingeier, Bernhard, additional, Gallmann, Caesar, additional, Etter, Gisela, additional, Huber, Benedikt, additional, Bertisch, Barbara, additional, Aebi-Popp, Karoline, additional, Haerry, David, additional, Kind, André, additional, Frey Tirri, Brigitte, additional, Broglie, Martina, additional, and Tarr, Philip, additional
- Published
- 2024
- Full Text
- View/download PDF
10. Diagnosis and Therapy of Community-Acquired Pneumonia in the Emergency Department: A Retrospective Observational Study and Medical Audit
- Author
-
Lüthi-Corridori, Giorgia, primary, Roth, Andrea I., additional, Boesing, Maria, additional, Jaun, Fabienne, additional, Tarr, Philip E., additional, Leuppi-Taegtmeyer, Anne B., additional, and Leuppi, Jörg D., additional
- Published
- 2024
- Full Text
- View/download PDF
11. ‘Problem patients and physicians’ failures': What it means for doctors to counsel vaccine hesitant patients in Switzerland
- Author
-
Deml, Michael J., Buhl, Andrea, Notter, Julia, Kliem, Paulina, Huber, Benedikt M., Pfeiffer, Constanze, Burton-Jeangros, Claudine, and Tarr, Philip E.
- Published
- 2020
- Full Text
- View/download PDF
12. The gut microbiome as an early biomarker of preclinical Alzheimer disease
- Author
-
Ances, Beau, primary, Ferreiro, Aura L., additional, Choi, JooHee, additional, Ryou, Jian, additional, Newcomer, Erin, additional, Stark, Susan L., additional, Benzinger, Tammie L.S., additional, Holtzman, David M., additional, Fagan, Anne M., additional, Schindler, Suzanne E., additional, Cruchaga, Carlos, additional, Butt, Omar Hameed, additional, Morris, John C, additional, Tarr, Philip, additional, and Dantas, Gautam, additional
- Published
- 2023
- Full Text
- View/download PDF
13. “We treat humans, not herds!”: A qualitative study of complementary and alternative medicine (CAM) providers’ individualized approaches to vaccination in Switzerland
- Author
-
Deml, Michael J., Notter, Julia, Kliem, Paulina, Buhl, Andrea, Huber, Benedikt M., Pfeiffer, Constanze, Burton-Jeangros, Claudine, and Tarr, Philip E.
- Published
- 2019
- Full Text
- View/download PDF
14. Systematic De-escalation of Successful Triple Antiretroviral Therapy to Dual Therapy with Dolutegravir plus Emtricitabine or Lamivudine in Swiss HIV-positive Persons
- Author
-
Diaco, Natascha D., Strickler, Claudio, Giezendanner, Stéphanie, Wirz, Sebastian A., and Tarr, Philip E.
- Published
- 2018
- Full Text
- View/download PDF
15. Antiretroviral Drug Exposure and Response in Obese and Morbidly Obese People With Human Immunodeficiency Virus (HIV): A Study Combining Modelling and Swiss HIV Cohort Data.
- Author
-
Berton, Mattia, Bettonte, Sara, Stader, Felix, Decosterd, Laurent, Tarr, Philip E, Livio, Françoise, Cavassini, Matthias, Braun, Dominique L, Kusejko, Katharina, Hachfeld, Anna, Bernasconi, Enos, Calmy, Alexandra, Schmid, Patrick, Battegay, Manuel, Marzolini, Catia, and Study, the Swiss HIV Cohort
- Subjects
HIV infections ,OBESITY ,HIV-positive persons ,VIRAL load ,ANTIRETROVIRAL agents ,MORBID obesity ,HEALTH outcome assessment ,TREATMENT effectiveness ,DRUG monitoring ,RESEARCH funding ,SWISS ,BODY mass index ,EVALUATION - Abstract
Background Obesity is increasingly prevalent among people with HIV (PWH) and can possibly result in suboptimal antiretroviral drug (ARV) exposure and response. However, this has not been thoroughly evaluated given that obese PWH are underrepresented in clinical trials. We performed virtual trials using physiologically based pharmacokinetic (PBPK) modelling combined with observed clinical data to provide ARV dosing guidance in obese individuals. Methods Each trial included a cohort of virtual adults with a body mass index (BMI) between 18.5 and 60 kg/m
2 . Therapeutic drug-monitoring data from the Swiss HIV Cohort Study (SHCS) were used to verify the predictive performance of the model. Subsequently, the model was applied to predict the pharmacokinetics of ARVs for different obesity classes. The association between ARV plasma concentrations and virological response was investigated in obese and nonobese individuals. Results The PBPK model predicted an average reduction in ARV exposure of ∼20% and trough concentrations of ∼6% in obese (BMI ≥30 kg/m2 ) compared with nonobese (BMI: 18.5–25 kg/m2 ) individuals, consistent with observed clinical data. Etravirine and rilpivirine were the most impacted, especially in individuals with BMI >40 kg/m2 whose trough concentrations were below the clinical target threshold. Obese PWH in the SHCS did not have a higher rate of unsuppressed viral load than nonobese PWH. Conclusions The concentrations of ARVs are modestly reduced in obese individuals, with no negative impact on the virological response. Our data provide reassurance that standard doses of ARVs are suitable in obese PWH, including those who gained substantial weight with some of the first-line ARVs. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
16. Incidence of sexually transmitted infections and association with behavioural factors: Time‐to‐event analysis of a large pre‐exposure prophylaxis (PrEP) cohort.
- Author
-
Hovaguimian, Frédérique, Kouyos, Roger D., Kusejko, Katharina, Schmidt, Axel J., Tarr, Philip E., Bernasconi, Enos, Braun, Dominique L., Calmy, Alexandra, Notter, Julia, Stoeckle, Marcel, Surial, Bernard, Christinet, Vanessa, Darling, Katharine E. A., Depmeier, Carsten, Läuchli, Severin, Reinacher, Matthias, Rasi, Manuela, Nicca, Dunja, Bruggmann, Philip, and Haerry, David
- Subjects
SEXUALLY transmitted disease diagnosis ,PREVENTION of sexually transmitted diseases ,SYPHILIS epidemiology ,EPIDEMIOLOGY of sexually transmitted diseases ,CHLAMYDIA ,GONORRHEA ,CONFIDENCE intervals ,TIME ,HUMAN sexuality ,HEALTH outcome assessment ,MEDICAL screening ,PRE-exposure prophylaxis ,HUMAN services programs ,RISK assessment ,SEX customs ,RESEARCH funding ,HEALTH behavior ,DESCRIPTIVE statistics ,MEN who have sex with men ,BACTERIAL diseases ,DATA analysis software ,LONGITUDINAL method ,PROPORTIONAL hazards models - Abstract
Objectives: Our objective was to obtain long‐term data on the incidence of sexually transmitted infections (STIs) and their association with behavioural factors after widespread pre‐exposure prophylaxis (PrEP) implementation. Methods: This was a time‐to‐event analysis of a national PrEP cohort in Switzerland (SwissPrEPared study). Participants were people without HIV interested in taking PrEP with at least two STI screening visits. Primary outcomes were incidence rate of gonorrhoea, chlamydia, and syphilis. The association between behavioural factors and STI diagnosis was expressed using hazard ratios. We adjusted for testing frequency and calendar year. Results: This analysis included 3907 participants enrolled between April 2019 and April 2022, yielding 3815.7 person‐years of follow‐up for gonorrhoea (15 134 screenings), 3802.5 for chlamydia (15 141 screenings), and 3858.6 for syphilis (15 001 screenings). The median age was 39 years (interquartile range [IQR] 32–47), 93.8% (n = 3664) identified as men who have sex with men (MSM). The incidence was 22.8 (95% confidence interval [CI] 21.3–24.4) per 100 person‐years for gonorrhoea, 26.3 (95% CI 24.7–28.0) for chlamydia, and 4.4 (95% CI 3.8–5.1) for syphilis. Yearly incidence rates decreased between 2019 (all bacterial STIs: 81.6; 95% CI 59.1–109.9) and 2022 (all bacterial STIs: 49.8; 95% CI 44.6–55.3). Participants reporting chemsex substance use were at higher risk of incident STIs, as were those reporting multiple sexual partners. Younger age was associated with a higher risk of gonorrhoea and chlamydia. Conclusions: Incidence rates of bacterial STIs decreased over time. Young MSM, those with multiple partners, and those using chemsex substances were at increased risk of STIs. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. Impfungen bei Immunsuppression
- Author
-
Temizel, Ekrem, primary, Mssig, Christopher, additional, Wingeier, Bernhard, additional, Huber, Benedikt M., additional, Etter, Gisela, additional, Bollinger, Claudia Ruth, additional, Jahn, Kathleen, additional, Weisser Rohacek, Maja, additional, Burkhalter Pirovino, Felix, additional, Abela, Irene, additional, and Tarr, Philip, additional
- Published
- 2023
- Full Text
- View/download PDF
18. Vaccination en cas d'immunosuppression
- Author
-
Temizel, Ekrem, primary, Mssig, Christopher, additional, Wingeier, Bernhard, additional, Huber, Benedikt M., additional, Etter, Gisela, additional, Bollinger, Claudia Ruth, additional, Jahn, Kathleen, additional, Weisser Rohacek, Maja, additional, Burkhalter Pirovino, Felix, additional, Abela, Irene, additional, and Tarr, Philip, additional
- Published
- 2023
- Full Text
- View/download PDF
19. Pharmacists’ approaches to vaccination consultations in Switzerland: a qualitative study comparing the roles of complementary and alternative medicine (CAM) and biomedicine
- Author
-
Zimmermann, Clara, primary, Jusufoska, Meliha, additional, Tolic, Josipa, additional, Abreu de Azevedo, Marta, additional, Tarr, Philip E, additional, and Deml, Michael J, additional
- Published
- 2023
- Full Text
- View/download PDF
20. Antiretroviral drug exposure and response in obese and morbidly obese people with HIV: a study combining modelling and Swiss HIV Cohort data
- Author
-
Berton, Mattia, primary, Bettonte, Sara, additional, Stader, Felix, additional, Decosterd, Laurent, additional, Tarr, Philip E, additional, Livio, Françoise, additional, Cavassini, Matthias, additional, Braun, Dominique L, additional, Kusejko, Katharina, additional, Hachfeld, Anna, additional, Bernasconi, Enos, additional, Calmy, Alexandra, additional, Schmid, Patrick, additional, Battegay, Manuel, additional, and Marzolini, Catia, additional
- Published
- 2023
- Full Text
- View/download PDF
21. Infektionen bei älteren Menschen
- Author
-
Petitat, Olivier, primary, Berger, Matthias, additional, Colin-Benoit, Eugnie, additional, Bguelin, Charles, additional, Flckiger, Bernard, additional, Hurni, Bettina, additional, Ruffo, Massimo, additional, Rllin, Alexandra, additional, Etter, Gisela, additional, Heim, Martina, additional, Boggian, Katia, additional, and Tarr, Philip, additional
- Published
- 2023
- Full Text
- View/download PDF
22. Les infections chez les personnes âgées
- Author
-
Petitat, Olivier, primary, Berger, Matthias, additional, Colin-Benoit, Eugnie, additional, Bguelin, Charles, additional, Flckiger, Bernard, additional, Hurni, Bettina, additional, Ruffo, Massimo, additional, Rllin, Alexandra, additional, Etter, Gisela, additional, Heim, Martina, additional, Boggian, Katia, additional, and Tarr, Philip, additional
- Published
- 2023
- Full Text
- View/download PDF
23. 'Sonderbahres Heerpaucken-Instrument zu Tromben': Research, Reconstruction and the Sound of the One-Stringed Wooden Timpani Described by Daniel Speer (1687/1697)
- Author
-
Hirsch, Thilo and Tarr, Philip E.
- Published
- 2008
24. Infections de la main
- Author
-
Dietrich, Lna, primary, Berner, Isabell, additional, Pastor, Tatjana, additional, Fuest, Lena, additional, Sutter, Damian, additional, Genewein, Urs, additional, Guarino, Laetitia, additional, Schmid Thurneysen, Lisa, additional, Nissl, Sonja, additional, Bguelin, Charles, additional, Capaul, Regula, additional, Meynard, Anne, additional, Seitz, Luca, additional, Egli, Rainer, additional, Fricker, Renato, additional, Vgelin, Esther, additional, and Tarr, Philip, additional
- Published
- 2023
- Full Text
- View/download PDF
25. Infektionen der Hand
- Author
-
Dietrich, Lna, primary, Berner, Isabell, additional, Pastor, Tatjana, additional, Fuest, Lena, additional, Sutter, Damian, additional, Genewein, Urs, additional, Guarino, Laetitia, additional, Schmid Thurneysen, Lisa, additional, Nissl, Sonja, additional, Bguelin, Charles, additional, Capaul, Regula, additional, Meynard, Anne, additional, Seitz, Luca, additional, Egli, Rainer, additional, Fricker, Renato, additional, Vgelin, Esther, additional, and Tarr, Philip, additional
- Published
- 2023
- Full Text
- View/download PDF
26. Epigenetic ageing accelerates before antiretroviral therapy and decelerates after viral suppression in people with HIV in Switzerland: a longitudinal study over 17 years
- Author
-
Schoepf, Isabella C, primary, Esteban-Cantos, Andrés, additional, Thorball, Christian W, additional, Rodés, Berta, additional, Reiss, Peter, additional, Rodríguez-Centeno, Javier, additional, Riebensahm, Carlotta, additional, Braun, Dominique L, additional, Marzolini, Catia, additional, Seneghini, Marco, additional, Bernasconi, Enos, additional, Cavassini, Matthias, additional, Buvelot, Hélène, additional, Thurnheer, Maria Christine, additional, Kouyos, Roger D, additional, Fellay, Jacques, additional, Günthard, Huldrych F, additional, Arribas, José R, additional, Ledergerber, Bruno, additional, and Tarr, Philip E, additional
- Published
- 2023
- Full Text
- View/download PDF
27. Impact of Integrase Inhibitors on Cardiovascular Disease Events in People With Human Immunodeficiency Virus Starting Antiretroviral Therapy
- Author
-
Surial, Bernard; https://orcid.org/0000-0002-1402-974X, Chammartin, Frédérique, Damas, José; https://orcid.org/0000-0001-7724-6226, Calmy, Alexandra; https://orcid.org/0000-0002-1137-6826, Haerry, David, Stöckle, Marcel; https://orcid.org/0000-0002-0088-5078, Schmid, Patrick, Bernasconi, Enos; https://orcid.org/0000-0002-9724-8373, Fux, Christoph A, Tarr, Philip E; https://orcid.org/0000-0002-1488-5407, Günthard, Huldrych F; https://orcid.org/0000-0002-1142-6723, Wandeler, Gilles; https://orcid.org/0000-0002-5278-8763, Rauch, Andri; https://orcid.org/0000-0001-5297-6062, Swiss HIV Cohort Study, Surial, Bernard; https://orcid.org/0000-0002-1402-974X, Chammartin, Frédérique, Damas, José; https://orcid.org/0000-0001-7724-6226, Calmy, Alexandra; https://orcid.org/0000-0002-1137-6826, Haerry, David, Stöckle, Marcel; https://orcid.org/0000-0002-0088-5078, Schmid, Patrick, Bernasconi, Enos; https://orcid.org/0000-0002-9724-8373, Fux, Christoph A, Tarr, Philip E; https://orcid.org/0000-0002-1488-5407, Günthard, Huldrych F; https://orcid.org/0000-0002-1142-6723, Wandeler, Gilles; https://orcid.org/0000-0002-5278-8763, Rauch, Andri; https://orcid.org/0000-0001-5297-6062, and Swiss HIV Cohort Study
- Abstract
BACKGROUND Integrase strand transfer inhibitors (INSTIs) have been associated with an increased risk for cardiovascular disease (CVD) events. We investigated the impact of starting INSTI-based antiretroviral therapy (ART) on CVD events among treatment-naïve people with human immunodeficiency virus using a target trial framework, which reduces the potential for confounding and selection bias. METHODS We included Swiss HIV Cohort Study participants who were ART-naïve after May 2008, when INSTIs became available in Switzerland. Individuals were categorized according to their first ART regimen (INSTI vs other ART) and were followed from ART start until the first of CVD event (myocardial infarction, stroke, or invasive cardiovascular procedure), loss to follow-up, death, or last cohort visit. We calculated hazard ratios and risk differences using pooled logistic regression models with inverse probability of treatment and censoring weights. RESULTS Of 5362 participants (median age 38 years, 21% women, 15% of African origin), 1837 (34.3%) started INSTI-based ART, and 3525 (65.7%) started other ART. Within 4.9 years (interquartile range, 2.4-7.4), 116 CVD events occurred. Starting INSTI-based ART was not associated with an increased risk for CVD events (adjusted hazard ratio, 0.80; 95% confidence interval [CI], .46-1.39). Adjusted risk differences between individuals who started INSTIs and those who started other ART were -0.17% (95% CI, -.37 to .19) after 1 year, -0.61% (-1.54 to 0.22) after 5 years, and -0.71% (-2.16 to 0.94) after 8 years. CONCLUSIONS In this target trial emulation, we found no difference in short- or long-term risk for CVD events between treatment-naïve people with human immunodeficiency virus who started INSTI-based ART and those on other ART.
- Published
- 2023
28. Association of a Polygenic Risk Score With Osteoporosis in People Living With HIV: The Swiss HIV Cohort Study
- Author
-
Schwenke, Johannes M, Thorball, Christian W, Schoepf, Isabella C, Ryom, Lene, Hasse, Barbara, Lamy, Olivier, Calmy, Alexandra, Wandeler, Gilles, Marzolini, Catia; https://orcid.org/0000-0002-2312-7050, Kahlert, Christian R, Bernasconi, Enos, Kouyos, Roger D, Günthard, Huldrych F; https://orcid.org/0000-0002-1142-6723, Ledergerber, Bruno, Fellay, Jacques, Burkhalter, Felix, Tarr, Philip E; https://orcid.org/0000-0002-1488-5407, Swiss HIV Cohort Study, Schwenke, Johannes M, Thorball, Christian W, Schoepf, Isabella C, Ryom, Lene, Hasse, Barbara, Lamy, Olivier, Calmy, Alexandra, Wandeler, Gilles, Marzolini, Catia; https://orcid.org/0000-0002-2312-7050, Kahlert, Christian R, Bernasconi, Enos, Kouyos, Roger D, Günthard, Huldrych F; https://orcid.org/0000-0002-1142-6723, Ledergerber, Bruno, Fellay, Jacques, Burkhalter, Felix, Tarr, Philip E; https://orcid.org/0000-0002-1488-5407, and Swiss HIV Cohort Study
- Abstract
BACKGROUND Bone mineral density (BMD) loss may be accelerated in people with HIV (PLWH). It is unknown whether a polygenic risk score (PRS) is associated with low BMD in PLWH. METHODS Swiss HIV Cohort Study participants of self-reported European descent underwent ≥2 per-protocol dual x-ray absorptiometry (DXA) measurements ≥2 years apart (2011-2020). Univariable and multivariable odds ratios (ORs) for DXA-defined osteoporosis were based on traditional and HIV-related risk factors and a genome-wide PRS built from 9413 single-nucleotide polymorphisms associated with low BMD in the general population. Controls were free from osteoporosis/osteopenia on all DXA measurements. RESULTS We included 438 participants: 149 with osteoporosis and 289 controls (median age, 53 years; 82% male, 95% with suppressed HIV RNA). Participants with unfavorable osteoporosis PRS (top vs bottom quintile) had univariable and multivariable-adjusted osteoporosis ORs of 4.76 (95% CI, 2.34-9.67) and 4.13 (1.86-9.18), respectively. For comparison, hepatitis C seropositivity, 5-year tenofovir disoproxil fumarate exposure, and parent history of hip fracture yielded univariable osteoporosis ORs of 2.26 (1.37-3.74), 1.84 (1.40-2.43), and 1.54 (0.82-2.9). CONCLUSIONS In PLWH in Switzerland, osteoporosis was independently associated with a BMD-associated PRS after adjustment for established risk factors, including exposure to tenofovir disoproxil fumarate.
- Published
- 2023
29. Epigenetic ageing accelerates before antiretroviral therapy and decelerates after viral suppression in people with HIV in Switzerland: a longitudinal study over 17 years
- Author
-
Schoepf, Isabella C, Esteban-Cantos, Andrés, Thorball, Christian W; https://orcid.org/0000-0002-6869-6943, Rodés, Berta, Reiss, Peter; https://orcid.org/0000-0001-7896-6428, Rodríguez-Centeno, Javier, Riebensahm, Carlotta, Braun, Dominique L; https://orcid.org/0000-0003-4036-1030, Marzolini, Catia; https://orcid.org/0000-0002-2312-7050, Seneghini, Marco, Bernasconi, Enos; https://orcid.org/0000-0002-9724-8373, Cavassini, Matthias; https://orcid.org/0000-0003-0933-7833, Buvelot, Hélène, Thurnheer, Maria Christine; https://orcid.org/0000-0003-1357-0347, Kouyos, Roger D; https://orcid.org/0000-0002-9220-8348, Fellay, Jacques; https://orcid.org/0000-0002-8240-939X, Günthard, Huldrych F; https://orcid.org/0000-0002-1142-6723, Arribas, José R, Ledergerber, Bruno; https://orcid.org/0000-0002-6881-4401, Tarr, Philip E; https://orcid.org/0000-0002-1488-5407, Swiss HIV Cohort Study, Schoepf, Isabella C, Esteban-Cantos, Andrés, Thorball, Christian W; https://orcid.org/0000-0002-6869-6943, Rodés, Berta, Reiss, Peter; https://orcid.org/0000-0001-7896-6428, Rodríguez-Centeno, Javier, Riebensahm, Carlotta, Braun, Dominique L; https://orcid.org/0000-0003-4036-1030, Marzolini, Catia; https://orcid.org/0000-0002-2312-7050, Seneghini, Marco, Bernasconi, Enos; https://orcid.org/0000-0002-9724-8373, Cavassini, Matthias; https://orcid.org/0000-0003-0933-7833, Buvelot, Hélène, Thurnheer, Maria Christine; https://orcid.org/0000-0003-1357-0347, Kouyos, Roger D; https://orcid.org/0000-0002-9220-8348, Fellay, Jacques; https://orcid.org/0000-0002-8240-939X, Günthard, Huldrych F; https://orcid.org/0000-0002-1142-6723, Arribas, José R, Ledergerber, Bruno; https://orcid.org/0000-0002-6881-4401, Tarr, Philip E; https://orcid.org/0000-0002-1488-5407, and Swiss HIV Cohort Study
- Abstract
BACKGROUND: Accelerated epigenetic ageing can occur in untreated HIV infection and is partially reversible with effective antiretroviral therapy (ART). We aimed to make a long-term comparison of epigenetic ageing dynamics in people with HIV during untreated HIV infection and during suppressive ART. METHODS: In this longitudinal study, conducted over 17 years in HIV outpatient clinics in Switzerland, we applied 5 established epigenetic age estimators (epigenetic clocks) in peripheral blood mononuclear cells (PBMCs) in Swiss HIV Cohort Study participants before or during suppressive ART. All participants had a longitudinal set of PBMC samples available at four timepoints (T1-T4). T1 and T2 had to be 3 years or longer apart, as did T3 and T4. We assessed epigenetic age acceleration (EAA) and a novel rate of epigenetic ageing. FINDINGS: Between March 13, 1990, and Jan 18, 2018, we recruited 81 people with HIV from the Swiss HIV Cohort Study. We excluded one participant because a sample did not meet quality checks (transmission error). 52 (65%) of 80 patients were men, 76 (95%) were white, and the median patient age was 43 (IQR 37·5-47) years. Per year of untreated HIV infection (median observation 8·08 years, IQR 4·83-11·09), mean EAA was 0·47 years (95% CI 0·37 to 0·57) for Horvath's clock, 0·43 years (0·3 to 0·57) for Hannum's clock, 0·36 years (0·27 to 0·44) for SkinBlood clock, and 0·69 years (0·51 to 0·86) for PhenoAge. Per year of suppressive ART (median observation 9·8 years, IQR 7·2-11), mean EAA was -0·35 years (95% CI -0·44 to -0·27) for Horvath's clock, -0·39 years (-0·50 to -0·27) for Hannum's clock, -0·26 years (-0·33 to -0·18) for SkinBlood clock, and -0·49 years (-0·64 to -0·35) for PhenoAge. Our findings indicate that people with HIV epigenetically aged by a mean of 1·47 years for Horvath's clock, 1·43 years for Hannum's clock, 1·36 years for SkinBlood clock, and 1·69 years for PhenoAge per year of untreated HIV infection; and 0·65 years for Horvath's cl
- Published
- 2023
30. Leukocyte Count and Coronary Artery Disease Events in People With Human Immunodeficiency Virus: A Longitudinal Study
- Author
-
Avery, Emma F, Kleynhans, Julia N, Ledergerber, Bruno; https://orcid.org/0000-0002-6881-4401, Schoepf, Isabella C, Thorball, Christian W; https://orcid.org/0000-0002-6869-6943, Kootstra, Neeltje A, Reiss, Peter; https://orcid.org/0000-0001-7896-6428, Ryom, Lene, Braun, Dominique L; https://orcid.org/0000-0003-4036-1030, Thurnheer, Maria Christine; https://orcid.org/0000-0003-1357-0347, Marzolini, Catia; https://orcid.org/0000-0002-2312-7050, Seneghini, Marco, Bernasconi, Enos; https://orcid.org/0000-0002-9724-8373, Cavassini, Matthias; https://orcid.org/0000-0003-0933-7833, Buvelot, Hélène, Kouyos, Roger D; https://orcid.org/0000-0002-9220-8348, Fellay, Jacques; https://orcid.org/0000-0002-8240-939X, Günthard, Huldrych F; https://orcid.org/0000-0002-1142-6723, Tarr, Philip E; https://orcid.org/0000-0002-1488-5407, Swiss HIV Cohort Study, Avery, Emma F, Kleynhans, Julia N, Ledergerber, Bruno; https://orcid.org/0000-0002-6881-4401, Schoepf, Isabella C, Thorball, Christian W; https://orcid.org/0000-0002-6869-6943, Kootstra, Neeltje A, Reiss, Peter; https://orcid.org/0000-0001-7896-6428, Ryom, Lene, Braun, Dominique L; https://orcid.org/0000-0003-4036-1030, Thurnheer, Maria Christine; https://orcid.org/0000-0003-1357-0347, Marzolini, Catia; https://orcid.org/0000-0002-2312-7050, Seneghini, Marco, Bernasconi, Enos; https://orcid.org/0000-0002-9724-8373, Cavassini, Matthias; https://orcid.org/0000-0003-0933-7833, Buvelot, Hélène, Kouyos, Roger D; https://orcid.org/0000-0002-9220-8348, Fellay, Jacques; https://orcid.org/0000-0002-8240-939X, Günthard, Huldrych F; https://orcid.org/0000-0002-1142-6723, Tarr, Philip E; https://orcid.org/0000-0002-1488-5407, and Swiss HIV Cohort Study
- Abstract
BACKGROUND: People with human immunodeficiency virus (HIV; PWH) have increased cardiovascular risk. Higher leukocyte count has been associated with coronary artery disease (CAD) events in the general population. It is unknown whether the leukocyte-CAD association also applies to PWH. METHODS: In a case-control study nested within the Swiss HIV Cohort Study, we obtained uni- and multivariable odds ratios (OR) for CAD events, based on traditional and HIV-related CAD risk factors, leukocyte count, and confounders previously associated with leukocyte count. RESULTS: We included 536 cases with a first CAD event (2000-2021; median age, 56 years; 87% male; 84% with suppressed HIV RNA) and 1464 event-free controls. Cases had higher latest leukocyte count before CAD event than controls (median [interquartile range], 6495 [5300-7995] vs 5900 [4910-7200]; P < .01), but leukocytosis (>11 000/µL) was uncommon (4.3% vs 2.1%; P = .01). In the highest versus lowest leukocyte quintile at latest time point before CAD event, participants had univariable CAD-OR = 2.27 (95% confidence interval, 1.63-3.15) and multivariable adjusted CAD-OR = 1.59 (1.09-2.30). For comparison, univariable CAD-OR for dyslipidemia, diabetes, and recent abacavir exposure were 1.58 (1.29-1.93), 2.19 (1.59-3.03), and 1.73 (1.37-2.17), respectively. Smoking and, to a lesser degree, alcohol and ethnicity attenuated the leukocyte-CAD association. Leukocytes measured up to 8 years before the event were significantly associated with CAD events. CONCLUSIONS: PWH in Switzerland with higher leukocyte counts have an independently increased risk of CAD events, to a degree similar to traditional and HIV-related risk factors.
- Published
- 2023
31. Brief Report: Does Menopause Transition Influence Viral Suppression and Adherence in Women Living With HIV?
- Author
-
Hachfeld, Anna; https://orcid.org/0000-0001-9308-7130, Atkinson, Andrew; https://orcid.org/0000-0001-5834-8315, Stute, Petra, Calmy, Alexandra; https://orcid.org/0000-0002-1137-6826, Tarr, Philip E; https://orcid.org/0000-0002-1488-5407, Darling, Katharine E A; https://orcid.org/0000-0003-1449-3873, Babouee Flury, Baharak, Polli, Christian, Sultan-Beyer, Leila, Abela, Irene A; https://orcid.org/0000-0002-5566-8628, Aebi-Popp, Karoline; https://orcid.org/0000-0002-9337-900X, Swiss HIV Cohort Study (SHCS), Hachfeld, Anna; https://orcid.org/0000-0001-9308-7130, Atkinson, Andrew; https://orcid.org/0000-0001-5834-8315, Stute, Petra, Calmy, Alexandra; https://orcid.org/0000-0002-1137-6826, Tarr, Philip E; https://orcid.org/0000-0002-1488-5407, Darling, Katharine E A; https://orcid.org/0000-0003-1449-3873, Babouee Flury, Baharak, Polli, Christian, Sultan-Beyer, Leila, Abela, Irene A; https://orcid.org/0000-0002-5566-8628, Aebi-Popp, Karoline; https://orcid.org/0000-0002-9337-900X, and Swiss HIV Cohort Study (SHCS)
- Abstract
BACKGROUND: Increasing numbers of women living with HIV transition through menopause. It is unclear whether this transition has an impact on treatment adherence, viral suppression, psychiatric comorbidities, or drug use. We aimed at examining adherence and viral suppression during the perimenopausal period and explored the influence of psychiatric comorbidities and active injection drug use (IDU). SETTING: Retrospective Swiss HIV Cohort Study analysis from January 2010 to December 2018. METHODS: We explored perimenopausal and postmenopausal trends of viral blips, low-level viremia, viral failure, adherence, psychiatric comorbidities, and IDU using interrupted time series models. RESULTS: Rates of depression and psychiatric care increased during perimenopause before decreasing afterward. Negative treatment outcomes such as viral blips, low-level viremia, viral failure, and low adherence steadily declined while transitioning through menopause-this was also true for subgroups of women with depression, psychiatric treatment, and active IDU. CONCLUSIONS: Increased rates of depression and psychiatric care while transitioning through menopause do not result in lower rates of adherence or viral suppression in women living with HIV in Switzerland.
- Published
- 2023
32. Masern-Impfung: Nutzen und neue Herausforderungen
- Author
-
Baldesberger, Nadja, primary, Lucas Ramanathan, Pia, additional, Wingeier, Bernhard, additional, Etter, Gisela, additional, Gallmann, Caesar, additional, Schmid-Thurneysen, Lisa, additional, Posfay-Barbe, Klara, additional, Deml, Michael J., additional, Bguelin, Charles, additional, Huber, Benedikt M., additional, and Tarr, Philip, additional
- Published
- 2023
- Full Text
- View/download PDF
33. Vaccination contre la rougeole: avantages et nouveaux défis
- Author
-
Baldesberger, Nadja, primary, Lucas Ramanathan, Pia, additional, Wingeier, Bernhard, additional, Etter, Gisela, additional, Gallmann, Caesar, additional, Schmid-Thurneysen, Lisa, additional, Posfay-Barbe, Klara, additional, Deml, Michael J., additional, Bguelin, Charles, additional, Huber, Benedikt M., additional, and Tarr, Philip, additional
- Published
- 2023
- Full Text
- View/download PDF
34. Rougeole, vaccination contre la rougeole
- Author
-
Baldesberger, Nadja, primary, Lucas Ramanathan, Pia, additional, Wingeier, Bernhard, additional, Etter, Gisela, additional, Gallmann, Caesar, additional, Schmid-Thurneysen, Lisa, additional, Posfay-Barbe, Klara, additional, Deml, Michael J., additional, Bguelin, Charles, additional, Huber, Benedikt M., additional, and Tarr, Philip, additional
- Published
- 2023
- Full Text
- View/download PDF
35. Masern, Masernimpfung
- Author
-
Baldesberger, Nadja, primary, Lucas Ramanathan, Pia, additional, Wingeier, Bernhard, additional, Etter, Gisela, additional, Gallmann, Caesar, additional, Schmid-Thurneysen, Lisa, additional, Posfay-Barbe, Klara, additional, Deml, Michael J., additional, Bguelin, Charles, additional, Huber, Benedikt M., additional, and Tarr, Philip, additional
- Published
- 2023
- Full Text
- View/download PDF
36. Polygenic Risk Scores for Prediction of Subclinical Coronary Artery Disease in Persons Living With HIV: The Swiss HIV Cohort Study
- Author
-
Schoepf, Isabella C, Thorball, Christian W, Kovari, Helen, Ledergerber, Bruno, Buechel, Ronny R, Calmy, Alexandra, Weber, Rainer, Kaufmann, Philipp A, Nkoulou, René, Schwenke, Johannes M, Braun, Dominique L, Fellay, Jacques, Tarr, Philip E, Swiss HIV Cohort Study, and University of Zurich
- Subjects
10234 Clinic for Infectious Diseases ,610 Medicine & health ,10181 Clinic for Nuclear Medicine - Published
- 2023
37. Epigenetic ageing accelerates before antiretroviral therapy and decelerates after viral suppression in people with HIV in Switzerland: a longitudinal study over 17 years
- Author
-
Schoepf, Isabella C., Esteban-Cantos, Andres, Thorball, Christian W., Rodes, Berta, Reiss, Peter, Rodriguez-Centeno, Javier, Riebensahm, Carlotta, Braun, Dominique L., Marzolini, Catia, Seneghini, Marco, Bernasconi, Enos, Cavassini, Matthias, Buvelot, Helene, Thurnheer, Maria Christine, Kouyos, Roger D., Fellay, Jacques, Gunthard, Huldrych F., Arribas, Jose R., Ledergerber, Bruno, and Tarr, Philip E.
- Subjects
Psychiatry and Mental health ,Health (social science) ,age ,telomere length ,610 Medicine & health ,Geriatrics and Gerontology ,Family Practice ,infection - Abstract
Background Accelerated epigenetic ageing can occur in untreated HIV infection and is partially reversible with effective antiretroviral therapy (ART). We aimed to make a long-term comparison of epigenetic ageing dynamics in people with HIV during untreated HIV infection and during suppressive ART., Methods In this longitudinal study, conducted over 17 years in HIV outpatient clinics in Switzerland, we applied 5 established epigenetic age estimators (epigenetic clocks) in peripheral blood mononuclear cells (PBMCs) in Swiss HIV Cohort Study participants before or during suppressive ART. All participants had a longitudinal set of PBMC samples available at four timepoints (T1-T4). T1 and T2 had to be 3 years or longer apart, as did T3 and T4. We assessed epigenetic age acceleration (EAA) and a novel rate of epigenetic ageing., Findings Between March 13, 1990, and Jan 18, 2018, we recruited 81 people with HIV from the Swiss HIV Cohort Study. We excluded one participant because a sample did not meet quality checks (transmission error). 52 (65%) of 80 patients were men, 76 (95%) were white, and the median patient age was 43 (IQR 37 center dot 5-47) years. Per year of untreated HIV infection (median observation 8 center dot 08 years, IQR 4 center dot 83-11 center dot 09), mean EAA was 0 center dot 47 years (95% CI 0 center dot 37 to 0 center dot 57) for Horvath's clock, 0 center dot 43 years (0 center dot 3 to 0 center dot 57) for Hannum's clock, 0 center dot 36 years (0 center dot 27 to 0 center dot 44) for SkinBlood clock, and 0 center dot 69 years (0 center dot 51 to 0 center dot 86) for PhenoAge. Per year of suppressive ART (median observation 9 center dot 8 years, IQR 7 center dot 2-11), mean EAA was -0 center dot 35 years (95% CI -0 center dot 44 to -0 center dot 27) for Horvath's clock, -0 center dot 39 years (-0 center dot 50 to -0 center dot 27) for Hannum's clock, -0 center dot 26 years (-0 center dot 33 to -0 center dot 18) for SkinBlood clock, and -0 center dot 49 years (-0 center dot 64 to -0 center dot 35) for PhenoAge. Our findings indicate that people with HIV epigenetically aged by a mean of 1 center dot 47 years for Horvath's clock, 1 center dot 43 years for Hannum's clock, 1 center dot 36 years for SkinBlood clock, and 1 center dot 69 years for PhenoAge per year of untreated HIV infection; and 0 center dot 65 years for Horvath's clock, 0 center dot 61 years for Hannum's clock, 0 center dot 74 years for SkinBlood clock, and 0 center dot 51 years for PhenoAge, per year of suppressive ART. GrimAge showed some change in the mean EAA during untreated HIV infection (0 center dot 10 years, 0 center dot 02 to 0 center dot 19) and suppressive ART (-0 center dot 05 years, -0 center dot 12 to 0 center dot 02). We obtained very similar results using the rate of epigenetic ageing. Contribution of multiple HIV-related, antiretroviral, and immunological variables, and of a DNA methylation-associated polygenic risk score to EAA was small., Interpretation In a longitudinal study over more than 17 years, epigenetic ageing accelerated during untreated HIV infection and decelerated during suppressive ART, highlighting the importance of limiting the duration of untreated HIV infection.
- Published
- 2023
- Full Text
- View/download PDF
38. Leukocyte Count and Coronary Artery Disease Events in People with HIV: A Longitudinal Study
- Author
-
Avery, Emma F, Kleynhans, Julia N, Ledergerber, Bruno, Schoepf, Isabella C, Thorball, Christian W, Kootstra, Neeltje A, Reiss, Peter, Ryom, Lene, Braun, Dominique L, Thurnheer, Maria C, Marzolini, Catia, Seneghini, Marco, Bernasconi, Enos, Cavassini, Matthias, Buvelot, Hélène, Kouyos, Roger D, Fellay, Jacques, Günthard, Huldrych F, and Tarr, Philip E
- Subjects
610 Medizin und Gesundheit - Abstract
BACKGROUND People with HIV (PWH) have increased cardiovascular risk. Higher leukocyte count has been associated with coronary artery disease (CAD) events in the general population. It is unknown whether the leukocyte-CAD association also applies to PWH. METHODS In a case-control study nested within the Swiss HIV Cohort Study, we obtained uni- and multivariable odds ratios (OR) for CAD events, based on traditional and HIV-related CAD risk factors, leukocyte count, and confounders previously associated with leukocyte count. RESULTS We included 536 cases with a first CAD event (2000-2021; median age 56 years, 87% male, 84% with suppressed HIV-RNA) and 1464 event-free controls. Cases had higher latest leukocyte count prior to CAD event than controls (median [interquartile range], 6495 [5300-7995] vs. 5900 [4910-7200]; p 11000/uL) was uncommon (4.3% vs. 2.1%; p = 0.01). In the highest vs. lowest leukocyte quintile at latest time point prior to CAD event, participants had univariable CAD-OR = 2.27 (95% confidence interval, 1.63-3.15) and multivariable adjusted CAD-OR = 1.59 (1.09-2.30). For comparison, univariable CAD-OR for dyslipidemia, diabetes, and recent abacavir exposure were 1.58 (1.29-1.93), 2.19 (1.59-3.03), and 1.73 (1.37-2.17), respectively. Smoking and, to a lesser degree, alcohol and ethnicity attenuated the leukocyte-CAD association. Leukocytes measured up to 8 years pre-event were significantly associated with CAD events. CONCLUSIONS PWH in Switzerland with higher leukocyte counts have an independently increased risk of CAD events, to a degree similar to traditional and HIV-related risk factors.
- Published
- 2023
- Full Text
- View/download PDF
39. Cerebrospinal fluid HIV-1 escape in patients with neurocognitive symptoms: pooled data from a neuro-HIV platform and the NAMACO study
- Author
-
Filippidis, Paraskevas, Damas, Jose, Viala, Benjamin, Assal, Frederic, Tshikung, Olivier Nawej, Tarr, Philip, Derfuss, Tobias, Oberholzer, Michael, Jelcic, Ilijas, Hundsberger, Thomas, Sacco, Leonardo, Cavassini, Matthias, Du Pasquier, Renaud, and Darling, Katharine E A
- Subjects
610 Medicine & health - Abstract
BACKGROUND Despite modern antiretroviral therapy, HIV-1 RNA escape into the cerebrospinal fluid (CSF) may occur. We examined the prevalence of and factors associated with CSF HIV-1 escape among people living with HIV (PLWH) in Switzerland. SETTING The Neurocognitive Assessment in the Metabolic and Aging Cohort (NAMACO) study is an ongoing, prospective, longitudinal, multicenter study within the Swiss HIV Cohort Study. The neuro-HIV platform is a multi-disciplinary, single-day outpatient consultation at Lausanne University Hospital. METHODS We pooled data from the NAMACO study and the neuro-HIV platform participants who underwent lumbar puncture (LP) between 2011 and 2019. Both patient groups had neurocognitive symptoms. CSF HIV-1 escape was defined as the presence of quantifiable CSF HIV-1 RNA when plasma HIV-1 RNA was suppressed or CSF HIV-1 RNA greater than plasma HIV-1 RNA when the latter was detectable. RESULTS Of 1166 PLWH assessed, 288 underwent LP. CSF HIV-1 escape was observed in 25 PLWH (8.7%) of whom 19 (76%) had supressed plasma HIV-1 RNA. Characteristics of PLWH were comparable whether they had CSF HIV-1 escape or not, including comorbidities, time since HIV diagnosis (15 vs 16 years, p=0.9), median CD4 nadir (158.5/mm3 vs 171/mm3, p=0.6), antiretroviral CSF-Penetration-Effectiveness score (7 vs 7 points, p=0.8), neurocognitive diagnosis based on Frascati criteria and radiological findings. CONCLUSIONS In this large pooled sample of PLWH with neurocognitive symptoms, CSF HIV-1 escape occurred in 8.7% of PLWH. PLWH with CSF HIV-1 escape presented no distinctive clinical or paraclinical characteristics. We conclude that LP is unavoidable in confirming CSF HIV-1 escape.
- Published
- 2023
- Full Text
- View/download PDF
40. Infektionen der Hand
- Author
-
Dietrich, Léna, Berner, Isabell, Pastor, Tatjana, Fuest, Lena, Sutter, Damian, Genewein, Urs, Guarino, Laetitia, Schmid Thurneysen, Lisa, Nissl, Sonja, Béguelin, Charles, Capaul, Regula, Meynard, Anne, Seitz, Luca, Egli, Rainer, Fricker, Renato, Vögelin, Esther, and Tarr, Philip
- Subjects
610 Medicine & health ,General Medicine - Published
- 2023
41. Impact of integrase inhibitors on cardiovascular disease events in people with HIV starting antiretroviral therapy
- Author
-
Surial, Bernard, Chammartin, Frédérique, Damas, José, Calmy, Alexandra, Haerry, David, Stöckle, Marcel, Schmid, Patrick, Bernasconi, Enos, Fux, Christoph A, Tarr, Philip, Günthard, Huldrych F, Wandeler, Gilles, and Rauch, Andri
- Subjects
610 Medicine & health - Abstract
BACKGROUND Integrase strand transfer inhibitors (INSTI) have been associated with an increased risk for cardiovascular disease (CVD) events. We investigated the impact of starting INSTI-based antiretroviral therapy (ART) on CVD events among treatment-naïve people with HIV (PWH) using a target trial framework, which reduces the potential for confounding and selection bias. METHODS We included Swiss HIV Cohort Study participants who were ART-naïve after 05/2008, when INSTI became available in Switzerland. Individuals were categorized according to their first ART regimen (INSTI vs. other ART) and were followed from ART start until the first of CVD event (myocardial infarction, stroke, or invasive cardiovascular procedure), loss to follow-up, death, or last cohort visit. We calculated hazard ratios and risk differences using pooled logistic regression models with inverse probability of treatment and censoring weights. RESULTS Of 5362 participants (median age 38 years, 21% women, 15% of African origin), 1837 (34.3%) started INSTI-based ART, and 3525 (65.7%) started other ART. Within 4.9 years (IQR 2.4-7.4), 116 CVD events occurred. Starting INSTI-based ART was not associated with an increase in CVD events (adjusted hazard ratio 0.80, 95% confidence interval [CI] 0.46-1.39). Adjusted risk differences between individuals who started INSTI and those who started other ART were -0.17% (95% CI -0.37-0.19) after one year, -0.61% (-1.54-0.22) after 5 years, and -0.71% (-2.16-0.94) after 8 years. CONCLUSIONS In this target trial emulation, we found no difference in short or longer term risk for CVD events between treatment-naïve PWH who started INSTI-based and those on other ART.
- Published
- 2023
- Full Text
- View/download PDF
42. Impact of Integrase Inhibitors on Cardiovascular Disease Events in People With Human Immunodeficiency Virus Starting Antiretroviral Therapy.
- Author
-
Surial, Bernard, Chammartin, Frédérique, Damas, José, Calmy, Alexandra, Haerry, David, Stöckle, Marcel, Schmid, Patrick, Bernasconi, Enos, Fux, Christoph A, Tarr, Philip E, Günthard, Huldrych F, Wandeler, Gilles, Rauch, Andri, and Study, the Swiss HIV Cohort
- Subjects
HIV infection complications ,ANTI-HIV agents ,HIV integrase inhibitors ,STROKE ,CONFIDENCE intervals ,CARDIOVASCULAR diseases ,MYOCARDIAL infarction ,HIGHLY active antiretroviral therapy ,DESCRIPTIVE statistics ,RESEARCH funding ,LOGISTIC regression analysis ,DATA analysis software ,HIV - Abstract
Background Integrase strand transfer inhibitors (INSTIs) have been associated with an increased risk for cardiovascular disease (CVD) events. We investigated the impact of starting INSTI-based antiretroviral therapy (ART) on CVD events among treatment-naïve people with human immunodeficiency virus using a target trial framework, which reduces the potential for confounding and selection bias. Methods We included Swiss HIV Cohort Study participants who were ART-naïve after May 2008, when INSTIs became available in Switzerland. Individuals were categorized according to their first ART regimen (INSTI vs other ART) and were followed from ART start until the first of CVD event (myocardial infarction, stroke, or invasive cardiovascular procedure), loss to follow-up, death, or last cohort visit. We calculated hazard ratios and risk differences using pooled logistic regression models with inverse probability of treatment and censoring weights. Results Of 5362 participants (median age 38 years, 21% women, 15% of African origin), 1837 (34.3%) started INSTI-based ART, and 3525 (65.7%) started other ART. Within 4.9 years (interquartile range, 2.4–7.4), 116 CVD events occurred. Starting INSTI-based ART was not associated with an increased risk for CVD events (adjusted hazard ratio, 0.80; 95% confidence interval [CI],.46–1.39). Adjusted risk differences between individuals who started INSTIs and those who started other ART were −0.17% (95% CI, −.37 to.19) after 1 year, −0.61% (−1.54 to 0.22) after 5 years, and −0.71% (−2.16 to 0.94) after 8 years. Conclusions In this target trial emulation, we found no difference in short- or long-term risk for CVD events between treatment-naïve people with human immunodeficiency virus who started INSTI-based ART and those on other ART. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
43. Distinguishing Clinical and Research Risks in Pragmatic Clinical Trials: The Need for Further Stakeholder Engagement.
- Author
-
Wilfond, Benjamin S., Toraman Turk, Sinem, Kraft, Stephanie A., Weiss, Elliott M., Tarr, Philip I., Schnadower, David, and Freedman, Stephen B.
- Subjects
HYDRATION ,CONSENSUS (Social sciences) ,CLINICAL trials ,FLUID therapy ,HUMAN research subjects ,STAKEHOLDER analysis ,SCHOLARSHIPS ,RISK assessment ,RESEARCH ethics ,INFORMED consent (Medical law) ,BIOETHICS - Abstract
The authors consider the case of a pragmatic clinical trial that raises important questions between informed consent and the risks associated with complex interventions and high stakes outcomes. Topics discussed include an approach to the ethical questions that arose in this trial and the need for more empirical research to guide the approach to future pragmatic trials.
- Published
- 2023
- Full Text
- View/download PDF
44. Associations Between Antiretroviral Treatment and Avascular Bone Necrosis: The Swiss HIV Cohort Study
- Author
-
Bayard, Cornelia, Ledergerber, Bruno, Flepp, Markus, Lecompte, Thanh, Moulin, Estelle, Hoffmann, Matthias, Weber, Rainer, Staehelin, Cornelia, Di Benedetto, Caroline, Fux, Christoph A, Tarr, Philip E, Hasse, Barbara, Aubert, V, Battegay, M, Bernasconi, E, Böni, J, Braun, DL, Bucher, HC, Calmy, A, Cavassini, M, Ciuffi, A, Dollenmaier, G, Egger, M, Elzi, L, Fehr, J, Fellay, J, Furrer, H, Fux, CA, Günthard, HF, Haerry, D, Hasse, B, Hirsch, HH, Hoffmann, M, Hösli, I, Kahlert, C, Kaiser, L, Keiser, O, Klimkait, T, Kouyos, RD, Kovari, H, Ledergerber, B, Martinetti, G, Martinez de Tejada, B, Marzolini, C, Metzner, KJ, Müller, N, Nicca, D, Pantaleo, G, Paioni, P, Rauch, A, Rudin, C, Scherrer, AU, Schmid, P, Speck, R, Stöckle, M, Tarr, P, Trkola, A, Vernazza, P, Wandeler, G, Weber, R, and Yerly, S
- Published
- 2017
- Full Text
- View/download PDF
45. Interferon lambda 3/4 polymorphisms are associated with AIDS-related Kaposiʼs sarcoma
- Author
-
Bibert, Stéphanie, Wójtowicz, Agnieszka, Taffé, Patrick, Tarr, Philip E., Bernasconi, Enos, Furrer, Hansjakob, Günthard, Huldrych F., Hoffmann, Matthias, Kaiser, Laurent, Osthoff, Michael, Fellay, Jacques, Cavassini, Matthias, and Bochud, Pierre-Yves
- Published
- 2018
- Full Text
- View/download PDF
46. Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial
- Author
-
Blum, Claudine Angela, Nigro, Nicole, Briel, Matthias, Schuetz, Philipp, Ullmer, Elke, Suter-Widmer, Isabelle, Winzeler, Bettina, Bingisser, Roland, Elsaesser, Hanno, Drozdov, Daniel, Arici, Birsen, Urwyler, Sandrine Andrea, Refardt, Julie, Tarr, Philip, Wirz, Sebastian, Thomann, Robert, Baumgartner, Christine, Duplain, Hervé, Burki, Dieter, Zimmerli, Werner, Rodondi, Nicolas, Mueller, Beat, and Christ-Crain, Mirjam
- Published
- 2015
- Full Text
- View/download PDF
47. Sexuell übertragbare Infektionen: Chlamydien, Gonorrhoe, Syphilis
- Author
-
Schoepf, Isabella, primary, Hunziker, Milena, additional, Surber, Jonathan, additional, Bertisch, Barbara, additional, Hampel, Benjamin, additional, Meynard, Anne, additional, Brenner Cortazar, Maja, additional, Kulier, Regina, additional, Egli, Rolf, additional, Grandinetti, Tanja, additional, Etter, Gisela, additional, Dietrich, Lna G., additional, Haerry, David, additional, Capol, Svend, additional, Aebi Popp, Karoline, additional, Mller, Simon, additional, Schmidt, Axel J., additional, and Tarr, Philip, additional
- Published
- 2022
- Full Text
- View/download PDF
48. Maladies sexuellement transmissibles Chlamydia, gonorrhée, syphilis
- Author
-
Schoepf, Isabella, primary, Hunziker, Milena, additional, Surber, Jonathan, additional, Bertisch, Barbara, additional, Hampel, Benjamin, additional, Meynard, Anne, additional, Brenner Cortazar, Maja, additional, Kulier, Regina, additional, Egli, Rolf, additional, Grandinetti, Tanja, additional, Etter, Gisela, additional, Dietrich, Lna G., additional, Haerry, David, additional, Capol, Svend, additional, Aebi Popp, Karoline, additional, Mller, Simon, additional, Schmidt, Axel J., additional, and Tarr, Philip, additional
- Published
- 2022
- Full Text
- View/download PDF
49. Healthcare professional and professional stakeholders’ perspectives on vaccine mandates in Switzerland: A mixed-methods study
- Author
-
Dietrich, Léna G., primary, Lüthy, Alyssa, additional, Lucas Ramanathan, Pia, additional, Baldesberger, Nadja, additional, Buhl, Andrea, additional, Schmid Thurneysen, Lisa, additional, Hug, Lisa C., additional, Suzanne Suggs, L., additional, Speranza, Camilla, additional, Huber, Benedikt M., additional, Tarr, Philip E., additional, and Deml, Michael J., additional
- Published
- 2022
- Full Text
- View/download PDF
50. Health Care Professionals’ Interest in Vaccination Training in Switzerland: A Quantitative Survey
- Author
-
Lucas Ramanathan, Pia, primary, Baldesberger, Nadja, additional, Dietrich, Léna G., additional, Speranza, Camilla, additional, Lüthy, Alyssa, additional, Buhl, Andrea, additional, Gisin, Martina, additional, Koch, Roswitha, additional, Nicca, Dunja, additional, Suggs, L. Suzanne, additional, Huber, Benedikt M., additional, Deml, Michael J., additional, and Tarr, Philip E., additional
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.